Status:
RECRUITING
Immunotherapy: Care and Prevention of Infectious and Tumoral Diseases (ImmunoHUB)
Lead Sponsor:
Fondazione IRCCS Policlinico San Matteo di Pavia
Conditions:
SARS CoV-2
Liver Tumours
Eligibility:
All Genders
18-90 years
Brief Summary
The project comprises two research lines. In the line 1, human monoclonal antibodies toward SARS-CoV-2 will be generate and characterized by in vitro functional tests. In the line 2, in vitro tests wi...
Eligibility Criteria
Inclusion
- Line 1: - Age \>18 at time of signing informed consent form
- Signed informed consent form Line 2: - Primery liver tumor
- Age \>18 at time of signing informed consent form
- Signed informed consent form
Exclusion
- Line 1: - Active or history of neoplastic malignancy
- Active autoimmune disease ongoing treatment with immunosuppressive therapy
- Evidence of positive HIV, HCV, HBV test
- Diabetes
- Failure to sign informed consent form Line 2: - Concomitant diseases with life expectancy of less than 12 months
- Chronic autoimmune or inflammatory diseases
- Treatment with atezolizumab, bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib, checkpoint inhibitors and tyrosine kinase inhibitors or anti-VEGF therapies
- Other extrahepatic neoplasms occurring or in the last 3 years except for tumors resected with curative intent and without evidence of relapse for \>3 years prior to signing informed consent and considered low risk of relapse
- HIV infection
- Failure to sign informed consent form
Key Trial Info
Start Date :
May 30 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2027
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06914635
Start Date
May 30 2023
End Date
February 1 2027
Last Update
April 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, Pavia, Italy, 27100